biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
PD-L1/IDO Peptide Vaccine
Phase 1 · mab · High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
PD-L1/IDO Peptide Vaccine for High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma is a Phase 1 program (mab) at IO Biotech with 1 ClinicalTrials.gov record(s).
Internal code UCDCC#290
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IO Biotech
- Phase
- Phase 1
- Modality
- mab
- Indication
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Status
- active
- Trials
- 1